A COVID-19 vaccine is already being administered to Americans. Another could earn emergency use authorization in just a few days. But that’s just the start of the news for manufacturers of COVID-19 vaccines. In this Motley Fool Live video recorded on December 11, 2020, Corinne Cardina, head of the health and cannabis office, and Fool.com writer Keith Speights talk about two more stocks of COVID-19 vaccines with key results underway.
Corrine Cardina: My last topic for us before we try to answer a few Slido questions is to look to the companies that are next to cross that finish line, what do we know about the timeline for Johnson & johnson (NYSE: JNJ) and AstraZenecaof (NASDAQ: AZN) phase 3 data?
Keith Speights: Let’s start with Johnson & Johnson. Johnson & Johnson has kept their information a bit closer to the vest than a lot of these companies. I think it’s reasonable to expect J&J to release its interim results from its Phase 3 study early next year. I’ve said it before, I’ll say it again. I am extremely interested to see how effective they will be. We have news from J&J in early 2021.
AstraZeneca is a little interesting because they might have their current study data available around the same time as Johnson & Johnson. However, keep in mind that AstraZeneca’s higher effectiveness was in a group that received half a dose and then a full dose of their vaccine.
Originally, they did not have this dosing regimen in their US study. They said they were going to add this regimen to their US study. But the FDA requires two months of observation after the second dose.
It’s going to be interesting to do with AstraZeneca. This might put them off a bit if they waited to file an EUA application with the FDA until they had group results that could give them higher efficacy. I believe the verdict has yet to be rendered regarding AstraZeneca.